Dr. Usman's Cardiology Notes

Apixaban Dose Reduction: ABC Rule Explained (Age, Body Weight, Creatinine) Apixaban is a direct oral anticoagulant (DOAC) widely used for stroke prevention in non-valvular atrial fibrillation and for treatment and secondary prevention of venous thromboembolism. While the standard dose is 5 mg twice daily, dose reduction is crucial in selected patients to balance thromboembolic protection against bleeding risk. The ABC mnemonic offers a simple, bedside-friendly way to remember when dose reduction is indicated. Standard Apixaban Dose • 5 mg twice daily Reduced Apixaban Dose • 2.5 mg twice daily Key Rule Reduce the dose to 2.5 mg twice daily if the patient meets any two of the following three criteria (ABC). A – Age Age ≥ 80 years Advanced age is associated with reduced drug clearance, altered pharmacodynamics, and higher bleeding risk. Elderly patients often have frailty, comorbidities, and polypharmacy, all of which increase anticoagulant sensitivity. Clinical relevance • Higher peak pl...

  Rivaroxaban: Mechanism, Dosing, and Landmark Clinical Trials – A Complete Guide Rivaroxaban is one of the most widely used direct oral anticoagulants (DOACs) worldwide. With predictable pharmacokinetics, fixed dosing, and no routine monitoring requirements, it has rapidly replaced warfarin in many clinical scenarios. This article covers how rivaroxaban works, recommended dosing in major indications, and key trials that shaped its use in modern cardiovascular medicine. --- ⭐ What is Rivaroxaban? Rivaroxaban is an oral, selective Factor Xa inhibitor used for: Prevention of stroke in atrial fibrillation Treatment and secondary prevention of venous thromboembolism (VTE) Post-operative thromboprophylaxis Prevention of ischemic events in CAD/PAD (low-dose strategy) Being the first oral Factor Xa inhibitor approved globally, rivaroxaban set the foundation for a new era of anticoagulation therapy. --- 1. Mechanism of Action: How Rivaroxaban Works Rivaroxaban selectively and directly inhi...

Atrial Fibrillation Why AFib matters — beyond the heartbeat AFib is the most common sustained cardiac arrhythmia.  It is more than “just an irregular heartbeat”: it carries significant risks, including stroke, heart failure, reduced quality of life, and mortality.  Many people may not even know they have it — sometimes no symptoms, silent disease.  As the global population ages and cardiovascular risk factors (hypertension, diabetes, obesity) rise, AFib’s prevalence is increasing.  For clinicians: early detection, appropriate anticoagulation, rhythm/rate control, and lifestyle modification are critical. --- What happens in the heart (in plain language) Imagine your heart’s upper chambers (the atria) as concert halls where signals should arrive in perfect rhythm. In AFib: The atria don’t contract in a coordinated fashion; instead they “quiver” (fibrillate).  Many rapid, chaotic signals bombard the atrioventricular (AV) node and ventricles, so the heartbeat become...

  The missing link in the debate on OAC in dialysis patients is appropriate risk stratification. The CHA2DS2-VASc score is widely employed to stratify the risk of ischaemic stroke in patients with AF, superseding the previously used CHADS2 score because of its better discriminative value. OAC is officially recommended when patients with AF have CHA2DS2-VASc scores ≥2 for men and ≥3 for women [2]. When this criterion is applied to the HD population with AF, nearly all patients qualify for OAC. However, the incidence of stroke appears to be lower in HD patients with AF than in non-dialysis patients with similar CHA2DS2-VASc scores [30], implying that the CHA2DS2-VASc score overestimates stroke risk in dialysis patients. In addition, the high risk of mortality due to bleeding may outweigh the stroke risk in a substantial proportion of dialysis patients with AF.